Technical Analysis for ADAP - Adaptimmune Therapeutics plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ADAP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -2.18% | |
| 20 DMA Resistance | Bearish | -2.18% | |
| 180 Bearish Setup | Bearish Swing Setup | -2.18% | |
| BB Squeeze Ended | Range Expansion | -2.18% | |
| Bollinger Band Squeeze | Range Contraction | -2.76% | |
| Narrow Range Bar | Range Contraction | -2.76% | |
| Inside Day | Range Contraction | -2.76% | |
| MACD Bearish Signal Line Cross | Bearish | -0.80% | |
| Bollinger Band Squeeze | Range Contraction | -0.80% | |
| 20 DMA Resistance | Bearish | -2.38% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 03/01/2021
Adaptimmune Therapeutics plc Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Acid Solid Tumors Immunotherapy Cancer Treatments Cancer Immunotherapy Virotherapy Small Cell Lung Cancer Ovarian Cancer Melanoma Non Small Cell Lung Cancer Acids Multiple Myeloma Peptides Sarcoma Novi Hematological Malignancies Oncolytics Biotech Adoptive Cell Transfer Immunotherapy Product Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Immunotherapy Product Amino Acids Cancer Immunotherapy Products Immunotherapy Products Breast And Lung Cancer Esophageal Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.4 |
| 52 Week Low | 3.2 |
| Average Volume | 858,011 |
| 200-Day Moving Average | 6.57 |
| 50-Day Moving Average | 5.57 |
| 20-Day Moving Average | 5.18 |
| 10-Day Moving Average | 5.11 |
| Average True Range | 0.37 |
| ADX | 10.56 |
| +DI | 20.82 |
| -DI | 22.02 |
| Chandelier Exit (Long, 3 ATRs ) | 4.94 |
| Chandelier Exit (Short, 3 ATRs ) | 5.86 |
| Upper Bollinger Band | 5.62 |
| Lower Bollinger Band | 4.74 |
| Percent B (%b) | 0.21 |
| BandWidth | 16.91 |
| MACD Line | -0.13 |
| MACD Signal Line | -0.12 |
| MACD Histogram | -0.0077 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.26 | ||||
| Resistance 3 (R3) | 5.25 | 5.14 | 5.20 | ||
| Resistance 2 (R2) | 5.14 | 5.06 | 5.14 | 5.18 | |
| Resistance 1 (R1) | 5.04 | 5.01 | 4.98 | 5.04 | 5.17 |
| Pivot Point | 4.92 | 4.92 | 4.90 | 4.93 | 4.92 |
| Support 1 (S1) | 4.82 | 4.84 | 4.76 | 4.82 | 4.69 |
| Support 2 (S2) | 4.71 | 4.79 | 4.71 | 4.68 | |
| Support 3 (S3) | 4.60 | 4.71 | 4.66 | ||
| Support 4 (S4) | 4.60 |
